Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

to $1.00 per share which may be paid upon the achievement of certain regulatory and commercial milestones. The first CVR payment of $0.50 per share (or $87.5 million) would become payable when either (i) Cinryze is approved by the FDA for acute treatment of HAE and the FDA grants orphan exclusivity for Cinryze encompassing the acute treatment of HAE to the exclusion of all other human C1 inhibitor products or, (ii) orphan exclusivity for the acute treatment of HAE has not become effective for any third party's human C1 inhibitor product by October 21, 2010. The second CVR payment of $0.50 per share ($87.5 million) would become payable when Cinryze reaches at least $600 million in cumulative net product sales within 10 years of closing of the acquisition.

Looking ahead in 2009

ViroPharma is providing guidance for the year 2009 as a convenience to investors. The following guidance provided by ViroPharma are projections, based upon numerous assumptions, all of which are subject to certain risks and uncertainties. For a discussion of the risks and uncertainties associated with these forward looking statements, please see the Disclosure Notice below.

For the year 2009, ViroPharma expects the following

  • Net product sales are expected to be $250 to $270 million. This guidance assumes no generic versions of Vancocin are approved in 2009 and excludes any revenue guidance for Cinryze.

  • Research and development (R&D) and selling, general and administrative (SG&A) expenses, including the impact of SFAS 123R, are expected to be $130 to $145 million, which includes approximately $25 million of expenses and previous commitments related to maribavir. SFAS 123R expenses are expected to be between $11 and $13 million.

Conference Call and Webca
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... BioPlus Specialty Pharmacy (BioPlus) announces the hiring ... of Managed Care. In this role, Damm will build ... nation’s leading specialty pharmacies. , Damm, who is based ... pharmacy and biotech experience to his new position with ... and Pfizer. Prior to working in Healthcare Damm served ...
(Date:3/5/2015)... Park, NC (PRWEB) March 05, 2015 ... announced that Pierre Noel, M.D., Professor of Medicine, ... to the Company’s Board of Directors. ... “We are extremely fortunate to have Dr. Noel, ... country’s leading healthcare organization, join Entegrion’s Board. His ...
(Date:3/5/2015)... Conn. , March 5, 2015  UBM ... , a leading online community to help ... of the newest information available regarding the use ... of kidney cancer. March is ... are very few effective adjuvant treatment options for ...
(Date:3/5/2015)...  In response to the incorrect assertions by LD, ... on February 12, 2015. Impeto Medical SAS and ... and their SUDOSCAN® devices have been proven to provide ... to have the courts decide this dispute rather than ... articles written by Key Opinion Leaders, published by significant ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Announces Hiring of New Vice President of Managed Care: Jamie Damm 2Entegrion Announces Appointment of Pierre Noel, MD, to Its Board of Directors 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 3Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2
... MailFoundry , a provider of anti-spam appliances and solutions, ... spam tactics known as botnet e-mail harvesting ... company's chief executive said the new RedListing anti-spam layer, produced ... no false positives and realtime detection capabilities. , ,David C. ...
... Madison, Wis. - With its first accelerator building fully ... ground this spring on a new, 50,000 square foot Accelerator ... to Third Wave Technologies, will help firms that are ready ... incubator for start-up technology companies. Suites will range in size ...
... , director of technology programs for the University of Wisconsin-Madison, ... as he demonstrates in Part II of this interview. In ... issues. In Part II (below), he addresses creating a culture ... Converse also is a featured speaker at the Fusion ...
Cached Biology Technology:Research park to add accelerator suites 2
(Date:2/5/2015)...  It is gratifying to see that the Obama ... science as a means to better understand human biology, ... was honored to participate in today,s White House event ... Since the 1980s my teams have been ... sequenced genome of a free living organism, the first ...
(Date:1/22/2015)... FindBiometrics, the leading source of biometrics industry news, interviews and ... "When we launched FindBiometrics 12 years ago the ... founder and CEO of FindBiometrics. "Now it,s maturing very quickly. ... players on a very broad scale.  We are known for ...
(Date:1/22/2015)... Jan. 16, 2015  A man-made form of insulin delivered ... mental capabilities in adults with mild cognitive impairment and ... by researchers at Wake Forest Baptist Medical Center. ... amnesic mild cognitive impairment (MCI) or mild to moderate ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... This release is available in German . ... interglacial epoch, around 115,000 years ago, there were significant ... transition from the Eemian Interglacial to the Weichselian Glacial ... with possibly at least two warming events. This is ...
... Sergiu M. Gorun, PhD, associate professor of chemistry ... www.njit.edu , was awarded a patent today for ... Compositions of Perfluoroalkyl Perfluoro-Phthalocyanine Compounds" (US Patent Number ... These new materials are comprised of organic ...
... Blacksburg, Va. A scientific paper that describes a ... biological processes has exceeded 500 citations in the ISI ... the impact of scientific publications. The Systems Biology Markup ... quantitative models of biochemical networks between different computer software ...
Cached Biology News:Were short warm periods typical for transitions between interglacial and glacial epochs? 2NJIT researcher awarded patent for hydrophobic, corrosion-resistant coating 2After 5 years, free systems biology markup language has proven popular 2After 5 years, free systems biology markup language has proven popular 3
Mouse Wnt-11 Affinity Purified Polyclonal Ab...
...
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
Use the DUALmembrane kit 3 to carry out DUALmembrane interaction analysis and cDNA library screening to characterize interactions between integral membrane proteins and to identify novel interaction ...
Biology Products: